![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1423673
¼¼°èÀÇ ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ ¹× Áö¿ªº° ºÐ¼®Pediatric Perfusion Systems Market Forecasts to 2030 - Global Analysis By Product, By Application (Cardiac Surgeries, Organ Transplantation, Extracorporeal Life Support and Other Applications), End User and By Geography |
¼¼°è ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 3¾ï 4,696¸¸ ´Þ·¯·Î 2030³â±îÁö 6¾ï 2,616¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ µ¿¾È 8.8%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛÀº ½ÉÀå ¼ö¼ú Áß ½ÉÆó¿ìȸ¼úÀ» ÇÊ¿ä·Î ÇÏ´Â ¿µÀ¯¾Æ¿Í ¼Ò¾Æ¸¦ À§ÇØ Æ¯º°È÷ Á¦ÀÛµÈ ÀÇ·á¿ë ½Ã½ºÅÛÀÔ´Ï´Ù. ¼Ò¾ÆÀÇ Æ¯¼öÇÑ »ý¸®Çп¡ ¸ÂÃá ÀÌ ½Ã½ºÅÛ¿¡´Â ¼ÒÇü »ê¼Ò °ø±Þ ÀåÄ¡, ÆßÇÁ, Æ©ºê, ¸ð´ÏÅ͸µ ÀåÄ¡ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÀÌ ½Ã½ºÅÛÀº ¼ö¼ú Áß »ê¼Ò °ø±Þ, ü¿Â Á¶Àý, Ç÷¾× ¼øÈ¯°ú °°Àº Áß¿äÇÑ ±â´ÉÀ» À¯ÁöÇÏ¸é¼ ¼Ò¾Æ ½ÉÀå ¼ö¼ú ½Ã ¼Ò¾Æ ȯÀÚÀÇ Æ¯¼öÇÑ ¿ä±¸ »çÇ×À» °í·ÁÇÏ¿© ¾ÈÀüÇϰí È¿°úÀûÀ¸·Î ¼Ò¾Æ ½ÉÀå ¼ö¼úÀ» Áö¿øÇÕ´Ï´Ù.
¹Ì±¹½ÉÀåÇùȸÀÇ ÆÑÆ®½ÃÆ® 2022¿¡ µû¸£¸é, ¼±Ãµ¼º ½ÉÀ庴Àº ¹Ì±¹¿¡¼ ¸Å³â ¾à 4¸¸ ¸íÀÇ ¿µ¾Æ¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼±Ãµ¼º ½ÉÀåÁúȯ ¹ß»ý·ü Áõ°¡
Àü ¼¼°èÀûÀ¸·Î ¿µÀ¯¾Æ ¹× ¼Ò¾Æ ¼±Ãµ¼º ½ÉÀåÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ ½ÃÀåÀÇ Áß¿äÇÑ ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀνÄÀÌ ³ô¾ÆÁö°í Áø´Ü ´É·ÂÀÌ Çâ»óµÊ¿¡ µû¶ó ´õ ¸¹Àº »ç·ÊµéÀÌ Á¶±â¿¡ ¹ß°ßµÇ¾î °í±Þ ½ÉÀå ¼ö¼úÀÌ ÇÊ¿äÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛÀº ÀÌ·¯ÇÑ ¼ö¼ú¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, ¼Ò¾Æ ȯÀÚÀÇ ÀÛÀº ÇØºÎÇÐÀû ±¸Á¶¿Í µ¶Æ¯ÇÑ »ý¸®Àû ¿ä±¸ »çÇ׿¡ ¸Â´Â Ưº°ÇÑ Áö¿øÀ» Á¦°øÇÕ´Ï´Ù. ¼±Ãµ¼º ½ÉÀå ÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ½ÉÀå ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó È¿°úÀûÀÎ °ü·ù ½Ã½ºÅÛÀÇ Çʿ伺µµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
Àåºñ ¹× ½Ã¼úÀÇ ³ôÀº ºñ¿ë
¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ ¹× °ü·Ã ½Ã¼ú°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀ¸·Î ÀÎÇØ ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ ½ÃÀåÀÌ Å©°Ô À§ÃàµÇ°í ÀÖ½À´Ï´Ù. ¼Ò¾Æ ȯÀÚµéÀ» À§ÇØ ¸ÂÃãÈµÈ ÀåºñÀÇ Æ¯¼ö¼º°ú ¾ö°ÝÇÑ ¾ÈÀü ±âÁØ ¹× ÷´Ü ±â¼úÀÌ °áÇÕµÇ¾î ºñ¿ë »ó½Â¿¡ ÇÑ ¸òÀ» Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ À¯Áöº¸¼ö ¹× ¾÷±×·¹ÀÌµå ºñ¿ë°ú °íµµ·Î ¼÷·ÃµÈ ÀηÂÀÇ Çʿ伺ÀÌ Àüü ÁöÃâÀ» ´õ¿í Áõ°¡½ÃŰ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ôÀº ºñ¿ëÀº ƯÁ¤ ÀÇ·á ½Ã¼³°ú Áö¿ª¿¡¼ÀÇ Á¢±Ù¼ºÀ» Á¦ÇÑÇϰí, ¼Ò¾Æ ½ÉÀå ¼ö¼ú¿¡¼ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÇ Áß¿äÇÑ Çʿ伺¿¡µµ ºÒ±¸ÇÏ°í º¸±ÞÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù.
°í°´ ¸ÂÃãÇü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
¼Ò¾Æ ȯÀÚµéÀº ´Ù¾çÇÑ ÇØºÎÇÐÀû, »ý¸®Àû ¿ä±¸¸¦ °¡Áö°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ´Ù¾ç¼º¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ¸ÂÃãÇü ½Ã½ºÅÛ ¹× ±â¼ú¿¡ ´ëÇÑ Á߿伺ÀÌ °Á¶µÇ°í ÀÖ½À´Ï´Ù. Á¶Á¤ °¡´ÉÇÑ ÆßÇÁ, ¼ÒÇü »ê¼Ò °ø±Þ ÀåÄ¡, Ư¼ö ¸ð´ÏÅ͸µ ÀåÄ¡ µî ȯÀÚ ¸ÂÃãÇü ¼Ö·ç¼Ç¿¡ ÁßÁ¡À» µÐ ±â¾÷µéÀº ÀÌ·¯ÇÑ Ãß¼¼¸¦ Ȱ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ƯÁ¤ ȯÀÚÀÇ ¿ä±¸ »çÇ×À» ÃæÁ·ÇÏ´Â ¸ÂÃãÇü ¿É¼ÇÀ» Á¦°øÇÏ´Â °ÍÀº ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó °æÀï·ÂÀ» È®º¸ÇÏ°í ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛÀÇ Çõ½Å°ú ½ÃÀå È®ÀåÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù.
±Þ°ÝÇÑ ±â¼ú º¯È
ºü¸¥ ±â¼ú Çõ½ÅÀº ±âÁ¸ ½Ã½ºÅÛÀ» ³ëÈÄȽÃų À§ÇèÀÌ Àֱ⠶§¹®¿¡ ½ÃÀå¿¡ À§ÇùÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. ²÷ÀÓ¾ø´Â ¹ßÀüÀº ÀåºñÀÇ ¼ö¸í Áֱ⸦ ´ÜÃà½ÃÄÑ ±âÁ¸ ½Ã½ºÅÛÀÇ ³ëÈÄȸ¦ ¾Õ´ç±æ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼ ÀæÀº ¾÷±×·¹À̵å¿Í »õ·Î¿î ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ°¡ ÇÊ¿äÇϸç, ÀÌ´Â ÀÇ·á ½Ã¼³ÀÇ ºñ¿ëÀ» Áõ°¡½Ãų ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¾÷µ¥ÀÌÆ®µÈ ½Ã½ºÅÛ¿¡ ´ëÇÑ Á÷¿ø ±³À°ÀÌ ÇÊ¿äÇϰí, ÁøÈÇϴ ǥÁذúÀÇ È£È¯¼ºÀ» º¸ÀåÇÏ´Â °ÍÀº ¹°·ù»óÀÇ ¹®Á¦°¡ µÉ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ºü¸¥ ±â¼ú ¹ßÀü ¼Óµµ´Â ÇöÀç ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ¸¦ ¾ïÁ¦ÇÏ°í ½ÃÀåÀÇ ¾ÈÁ¤¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
COVID-19´Â ÀÌ·¯ÇÑ ½Ã½ºÅÛÀÌ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¼Ò¾Æ ½ÉÀå ¼ö¼úÀ» Æ÷ÇÔÇÑ ´ë±â ¼ö¼ú¿¡ È¥¶õÀ» ÀÏÀ¸ÄÑ ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. º´¿øÀÇ ¼ö¿ë·Â °¨¼Ò, ÀÚ¿ø ÀçºÐ¹è ¹× ¾ÈÀü Á¶Ä¡·Î ÀÎÇØ ÀÀ±Þ ¼ö¼úÀ» Á¦¿ÜÇÑ ¸ðµç ¼ö¼úÀÌ ¿¬±âµÇ¾ú½À´Ï´Ù. ÀÌ·Î ÀÎÇØ ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä°¡ ÀϽÃÀûÀ¸·Î °¨¼ÒÇÏ¿© ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ±×·¯³ª ¸¹Àº ¼Ò¾Æ ½ÉÀå ¼ö¼úÀº ±ä±Þ¼ºÀÌ ³ô±â ¶§¹®¿¡ ÀÌ·¯ÇÑ ¹®Á¦¿¡µµ ºÒ±¸Çϰí ÀÏÁ¤ÇÑ ¼ö¿ä°¡ À¯ÁöµÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¼Ò¾Æ »ê¼Ò °ø±Þ ÀåÄ¡ ºÐ¾ß°¡ °¡Àå Å« ½ÃÀåÀ¸·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»ó
¼Ò¾Æ¿ë »ê¼Ò °ø±Þ ÀåÄ¡ ºÐ¾ß´Â ¼Ò¾Æ ½ÉÀå ¼ö¼ú ½Ã ÇʼöÀûÀÎ »ê¼Ò °ø±Þ Áö¿øÀ» Á¦°øÇÏ´Â ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ¾î ½ÃÀåÀÇ ´ëºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¼úÀº ÀûÀº Ç÷¾×·®°ú ¼Ò¾Æ ƯÀ¯ÀÇ »ý¸®¿¡ ¸Â´Â Á¤È®ÇÑ »ê¼Ò °ø±ÞÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ư¼öÇÑ »ê¼Ò °ø±Þ ÀåÄ¡°¡ ¸Å¿ì Áß¿äÇÕ´Ï´Ù. ¶ÇÇÑ, ¼±Ãµ¼º ½ÉÀå ÁúȯÀÇ ¹ß»ý·ü Áõ°¡¿Í ¼Ò¾Æ ½ÉÀå ¼ö¼ú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î ÀÎÇØ È¿À²ÀûÀ̰í ÀûÀÀ·ÂÀÌ ³ôÀº »ê¼Ò °ø±Þ ÀåÄ¡ÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, ÀÌ ºÎ¹®ÀÌ ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛÀÇ ÇÙ½ÉÀ¸·Î ÀÚ¸® ÀâÀ¸¸ç ½ÃÀå ¿ìÀ§¸¦ È®º¸ÇÏ´Â ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷ÀÌ °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»ó
Á¦¾à ¹× ¹ÙÀÌ¿À ±â¾÷ ºÎ¹®Àº ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ¿¡ ÃÊÁ¡À» ¸ÂÃá ¿¬±¸°³¹ß Áõ°¡·Î ÀÎÇØ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ ±â¾÷µéÀº Çõ½ÅÀûÀÎ ±â¼ú, ¾à¹° °³¹ß, ¼Ò¾Æ ½ÉÀå ¼ö¼ú¿¡ ÇÊ¿äÇÑ Æ¯¼ö Àåºñ¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ ÅõÀÚ¸¦ Çϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ ȯÀÚ ¸ÂÃãÇü ¼Ö·ç¼Ç¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼ Á¦¾à ¹× »ý¸í°øÇÐ ±â¾÷µéÀÌ Ã·´Ü °ü·ù ½Ã½ºÅÛ °³¹ßÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¿¹Ãø ±â°£ µ¿¾È ÀÌ ºÐ¾ßÀÇ ³ôÀº ¼ºÀå·üÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ºÏ¹Ì Áö¿ªÀº ³ôÀº ¼öÁØÀÇ ÀÇ·á ÀÎÇÁ¶ó, dzºÎÇÑ R&D ÅõÀÚ, ³ôÀº ¼±Ãµ¼º ½ÉÀ庴 À¯º´·ü·Î ÀÎÇØ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ, ÀÌ Áö¿ª¿¡´Â ¼Ò¾Æ½ÉÀå¼¾ÅͰ¡ Àß °®Ãß¾îÁ® ÀÖ°í, ¿¬±¸±â°ü°ú Á¦¾à»ç °£ÀÇ Çù·Â ü°è°¡ Àß °®ÃçÁ® ÀÖ½À´Ï´Ù. ºÏ¹Ì´Â À¯¸®ÇÑ »óȯ Á¤Ã¥°ú ÁÖ¿ä ½ÃÀå ±â¾÷ÀÇ Á¸Àç·Î ÀÎÇØ Á¤±³ÇÑ ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛÀÇ Ã¤Åðú µµÀÔ¿¡ ÀÖ¾î ºÏ¹ÌÀÇ ¿ìÀ§¸¦ ´õ¿í °ÈÇÏ¿© Å« ½ÃÀå Á¡À¯À²À» È®º¸Çϰí ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀº ÀÇ·áºñ ÁöÃâ Áõ°¡, ¼Ò¾Æ ½ÉÀå Ä¡·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼Ò¾Æ Àα¸ Áõ°¡·Î ÀÎÇØ Å« ¼ºÀåÀ» ÀÌ·ê °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÈï±¹µéÀº ÀÇ·á ÀÎÇÁ¶ó °³¼±°ú ±â¼ú µµÀÔÀ» ¸ñ°ÝÇϰí ÀÖÀ¸¸ç, À̴ ÷´Ü °ü·ù ½Ã½ºÅÛ¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¼¼°è ±â¾÷°úÀÇ Á¦ÈÞ, Á¤ºÎ ÀÌ´Ï¼ÅÆ¼ºê, ¼Ò¾Æ ½ÉÀå ¼ö¼ú ¼¾ÅÍÀÇ È®´ë´Â ÀÌ Áö¿ªÀÇ Ã·´Ü ¼Ò¾Æ¿ë °ü·ù ½Ã½ºÅÛ µµÀÔ ¹× ÅëÇÕ¿¡ ÀÖ¾î »ó´çÇÑ ¼ºÀå ÀáÀç·Â¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Pediatric Perfusion Systems Market is accounted for $346.96 million in 2023 and is expected to reach $626.16 million by 2030 growing at a CAGR of 8.8% during the forecast period. Pediatric perfusion systems are specialised medical setups crafted specifically for infants and children requiring cardiopulmonary bypass during cardiac surgeries. Tailored to their unique physiologies, these systems include smaller oxygenators, pumps, tubing and monitoring devices. They maintain vital functions like oxygenation, temperature control and blood circulation during procedures, ensuring safe and effective support for pediatric cardiac surgery while considering the unique needs of younger patients.
According to American Heart Association, Inc.'s fact sheet 2022, congenital heart defects are expected to affect around 40,000 infants in the U.S. each year.
Rising incidence of congenital heart defects
The increasing prevalence of congenital heart defects among infants and children globally serves as a significant driver in the pediatric Perfusion systems market. With rising awareness and improved diagnostic capabilities, more cases are being identified early, necessitating advanced cardiac surgeries. Pediatric perfusion systems play a crucial role in these surgeries, providing specialised support tailored to the smaller anatomies and unique physiological requirements of pediatric patients. As the demand for corrective cardiac procedures rises due to the growing incidence of congenital heart defects, the need for effective perfusion systems amplifies accordingly.
High cost of equipment and procedures
The high cost associated with pediatric perfusion systems and related procedures poses a significant restraint on the market. The specialised nature of equipment tailored for pediatric patients, coupled with stringent safety standards and advanced technologies, contributes to elevated costs. Additionally, the expenses incurred in maintaining and upgrading these systems, along with the need for highly skilled personnel, further escalate the overall expenditure. This high cost limits accessibility for certain healthcare facilities or regions, hindering widespread adoption despite the critical need for these systems in pediatric cardiac surgeries.
Growing demand for customized solutions
Pediatric patients exhibit diverse anatomies and physiological needs, and there's a growing emphasis on tailored systems and technologies to address these variations. Companies focusing on adaptable, patient-specific solutions, such as adjustable pumps, smaller oxygenators, and specialised monitoring devices, can capitalise on this trend. Offering customised options that cater to specific patient requirements not only enhances patient outcomes but also establishes a competitive edge, fostering innovation and market expansion in pediatric perfusion systems.
Rapid technological changes
Rapid technological changes pose a threat to the market due to the risk of rendering existing systems obsolete. Continuous advancements may lead to shorter lifecycles for equipment, potentially making current systems outdated faster. This necessitates frequent upgrades or investments in newer technologies, increasing costs for healthcare facilities. Additionally, the need for training staff on updated systems and ensuring compatibility with evolving standards can create logistical challenges. This swift pace of technological evolution might deter investments in current solutions, impacting market stability.
The COVID-19 pandemic has influenced the market by causing disruptions in elective surgeries, including pediatric cardiac procedures, where these systems are crucial. Reduced hospital capacities, redirected resources, and safety measures resulted in deferred non-emergency surgeries. This decreased demand for pediatric perfusion systems temporarily, affecting market growth. However, the urgent nature of many pediatric cardiac surgeries has sustained some demand despite these challenges.
The pediatric oxygenators segment is expected to be the largest during the forecast period
The pediatric oxygenators segment is anticipated to dominate due to its pivotal role in providing essential oxygenation support during pediatric cardiac surgeries. As these procedures require precise and tailored oxygenation for smaller blood volumes and unique pediatric physiology, specialised oxygenators are crucial. Additionally, the rising incidence of congenital heart defects and the demand for pediatric cardiac interventions drive the need for efficient and adaptable oxygenators, positioning this segment as a cornerstone in pediatric perfusion systems and thus driving its expected market dominance.
The pharmaceutical and biotech companies segment is expected to have the highest CAGR during the forecast period
The pharmaceutical and biotech companies segment anticipates the highest growth rate owing to increased research and development focused on pediatric perfusion systems. These companies invest extensively in innovative technologies, drug development and specialised equipment catering to pediatric cardiac surgeries. With a growing emphasis on tailored solutions for pediatric patients, pharmaceutical and biotech firms are leading in developing advanced perfusion systems, thus driving the projected high growth rate in this segment during the forecast period.
North America is positioned to hold the largest market share due to advanced healthcare infrastructure, substantial R&D investments, and a high prevalence of congenital heart defects. Additionally, the region boasts well-established pediatric cardiac centers and collaborations between research institutes and pharmaceutical companies. Favorable reimbursement policies and the presence of key market players further contribute to North America's dominance in adopting and implementing sophisticated pediatric perfusion systems, securing a significant market share.
The Asia-Pacific region is set to experience significant growth owing to the rising healthcare expenditure, increasing awareness about pediatric cardiac care and a growing pediatric population. Emerging economies are witnessing improvements in healthcare infrastructure and technology adoption, fostering the demand for advanced perfusion systems. Moreover, collaborations with global players, government initiatives and expanding pediatric cardiac surgery centres contribute to the region's substantial growth potential in adopting and integrating sophisticated pediatric perfusion systems.
Key players in the market
Some of the key players in Pediatric Perfusion Systems Market include Baxter International Inc., Braile Biomedica, Edwards Lifesciences Corporation, Getinge Group, Hemovent GmbH, LeMaitre Vascular, Inc., LivaNova, Medtronic, MicroPort Scientific Corporation, Nipro Medical Corporation, Perfusion.com, Inc., Sorin Group, Spectrum Medical, Stryker Corporation, Terumo Cardiovascular and Xenios AG.
In December 2023, Vascular Perfusion Solutions (VPS), Inc., is a San Antonio based medical device startup company focused on developing novel prolonged organ preservation technologies prior to transplantation, has received a $25,000 grant from the Southwest-Midwest National Pediatric Device Innovation Consortium (SWPDC).
In March 2023, LivaNova PLC, a market-leading medical technology and innovation company, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Essenz™ Heart-Lung Machine (HLM). With FDA clearance, LivaNova initiates the commercial launch of Essenz in the U.S. The Company also recently received approval for the Essenz HLM from Health Canada and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).